The South East Asia And South Asia Industrial Microbiology Market, estimated at USD 838.2 Mn in 2025, is expected to exhibit a CAGR of 6% and reach USD 1,260.3 Mn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
Key market players are focusing on adopton of growth strategies such as launch of new products, and this is expected to drive the South East Asia and South Asia industrial microbiology market. For instance, in July 2021, Thermo Fisher Scientific, Inc., a biotechnology company, launched a first-in-market CO2 incubator that combines optimal cell growth capabilities with certified cleanroom compatibility, and thus, addressing the growing need among biotechnology, biopharmaceutical, and clinical labs for high-performance incubation systems that meet stringent cleanroom and cGMP standards.
South East Asia and South Asia Industrial Microbiology Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding the transportation of things from one place to another.
The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sector, which has been majorly impacted by the COVID-19 pandemic. The pandemic had negatively impacted the South East Asia and South Asia industrial microbiology market by affecting directly on development, production, and supply of medical devices. It also affected growth of the pharmaceutical businesses of various companies globally, due to lockdowns implemented by governments of several countries. The nationwide lockdowns led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the pharmaceuticals and kits for diagnostic and therapeutic use. For instance, in September 2020, according to the article published by Frontiers S.A. Journal,, several animal processing plants were shut down in the U.S. in order to prevent the spread of the coronavirus infection. This led to the decrease in the rate of production of pharmaceutical products.
South East Asia and South Asia Industrial Microbiology Market: Key Developments
On June 29, 2023, Beckman Coulter Life Sciences, a leader in laboratory automation and innovation, launched a new Light Array Module (LAM) for the popular BioLector XT Microbioreactor. This advancement allows high-throughput screening and process optimization for a wide range of phototrophic organisms including microalgae and cyanobacteria. Utilizing real-time biomass, chlorophyll concentration, and fluorescence measurements, the BioLector XT Microbioreactor with LAM provides users real-time data without the need for pipetting samples for analysis.
On March 27, 2023, BIOMÉRIEUX, a biotechnology company, announced the partnership with Interscience, a developer of scientific instruments, to develop the 3P STATION, an automated system. This automated system is designed for the pharmaceutical industry to improve environmental monitoring.
On January 11, 2023, Becton, Dickinson and Company, a leading global medical technology company, introduced a new, robotic track system for the BD Kiestra microbiology laboratory solution that automates lab specimen processing, that can help to reduce manual labor and wait time for results. The new BD Kiestra 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra modules and is scalable to meet labs' unique and evolving needs.